# Bioverge

> Bioverge is a VC fund in San Francisco backing Biotechnology and Health Care. See 57 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 57
- Last investment: Sep 2024
- Lead investor: 0%
- Last fund: Jan 2022
- Last updated: Aug 2026
- LinkedIn: https://in.linkedin.com/company/bioverge
- Website: https://bioverge.com/

Bioverge is a venture capital firm specializing in emerging healthcare startups. The firm operates Bioverge.com, an investment platform that aims to democratize access to startups solving healthcare’s biggest challenges and accelerate their progress.

## Contacts

5 contacts available for Bioverge. Shizune tracks 3 team members at Bioverge. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bioverge?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 25 | 44% |
| Health Care | 19 | 33% |
| Therapeutics | 12 | 21% |
| Life Science | 8 | 14% |
| Medical | 6 | 11% |

43 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 29 | 51% |
| Series A | 9 | 16% |
| Series B | 5 | 9% |
| Venture - Series Unknown | 3 | 5% |
| Series C | 1 | 2% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 37 | 65% |
| Ireland | 1 | 2% |
| United Kingdom | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Marianne Santaguida | Entrepreneur In Residence | 0 | https://shizune.co/investors/profile/marianne-santaguida |
| Neil Littman | Founding Partner & CEO | 0 | https://shizune.co/investors/profile/neil-littman |
| Rick Gibb | Founding Partner & COO | 0 | https://shizune.co/investors/profile/rick-gibb |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| EnClear Therapies | EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will targetimproving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). |  | Venture - Series Unknown | Sep 03, 2024 |  |
| UBERDOC | Established in 2016, UBERDOC provides priority access to the best doctors for an affordable, transparent price. The company offers free directory listing to qualified Medical Doctors and free membership to patients. Its unrivaled mobile technology and transparent pricing structure make it simple and easy for patients needing urgent medical care toinstantly connect to a choice of specialists without requiring a referral, insurance paperwork or having to wait many months for an appointment. The Boston-based, privately held company was founded by Paula Muto, MD, FACS, a Vascular and General Surgeon. Muto has been credited as an expert in the healthcare industry by publications like Huffington Post, Fox business, Becker’s Hospital Review, General Surgery News, and Boston magazine.UBERDOC, Inc., a digital platform for direct-pay healthcare, has grown from a Boston-based startup to a nationally recognized member of the digital health community, having participated in several conferences in Boston, New York, Chicago and San Francisco. Thousands of doctors across the US are enrolled on the UBERDOC platform with patients using its service daily.At www.uber-docs.com (https://uber-docs.com/), patients search by medical specialty, book and pay for a doctor appointment using an HSA (Health Savings Account), FSA or credit card, and see the Medical Doctor at the scheduled time and place. A $50 transaction fee secures the appointment, and $250 is charged after the consult is determined completed by the doctor. Doctors are paid immediately and directly through the UBERDOC platform. |  | Venture - Series Unknown | Jul 09, 2024 |  |
| My Diabetes Tutor | My Diabetes Tutor was recently named the first accredited diabetes education telehealth program in California by the American Association of Diabetes Educators (AADE), a National Accredited Organization (NAO). This will provide individuals with diabetes increased access to high quality diabetes education services. My Diabetes Tutor was named thefirst accredited diabetes education telehealth program in California by the Association of Diabetes Care and Education Specialists (ADCES), (etc). My Diabetes Tutor recently did a scientific presentation at the American Diabetes Association Scientific Meeting 2022 and our abstract is published in the Diabetes Journal. |  |  | Jul 27, 2023 |  |
| My Diabetes Tutor | My Diabetes Tutor was recently named the first accredited diabetes education telehealth program in California by the American Association of Diabetes Educators (AADE), a National Accredited Organization (NAO). This will provide individuals with diabetes increased access to high quality diabetes education services. My Diabetes Tutor was named thefirst accredited diabetes education telehealth program in California by the Association of Diabetes Care and Education Specialists (ADCES), (etc). My Diabetes Tutor recently did a scientific presentation at the American Diabetes Association Scientific Meeting 2022 and our abstract is published in the Diabetes Journal. | $3M | Seed | Jul 27, 2023 |  |
| Modulo Bio | Modulo Bio simulates the neuroimmune system to find medication candidates that target microglia cells. The organization's proprietary neuroimmune platform combines the most recent developments in stem cell biology and neuroscience with software, automation, and artificial intelligence to create novel treatments. | $8M | Seed | Jun 01, 2023 |  |
| Jelikalite | Jelikalite creates medical equipment for kids with autism spectrum disorders. They emphasize using non-invasive innovative methods to promote the brain health of children. It is a wearable medical device. It combines infrared light, sensors, an AI personalization platform, and non-invasive brain stimulation. |  | Seed | Feb 01, 2023 |  |
| Jelikalite | Jelikalite creates medical equipment for kids with autism spectrum disorders. They emphasize using non-invasive innovative methods to promote the brain health of children. It is a wearable medical device. It combines infrared light, sensors, an AI personalization platform, and non-invasive brain stimulation. |  | Seed | Dec 21, 2022 |  |
| Eigen Therapeutics | Eigen Therapeutics is a biotechnology company on a mission to make therapies that make cancer easier to find and eliminate. Eigen is focused on the development of “priming” therapies, therapies that help targeted therapies reach their full potential by addressing cancer heterogeneity, making cancer cells more vulnerable and/or making healthycells more resilient to treatment. Eigen is building a high-throughput discovery platform to explore the space of priming therapies, leveraging proprietary machine learning algorithms to discover novel associations, new classes of drugs, and new potential therapies that change a cell's state to make it more vulnerable to a targeted therapy. The Eigen platform represents the intersection of biology and engineering, and includes robotic systems, laboratory operations software, and machine learning analysis pipelines—all developed in-house—with the ultimate goal of saving more lives. | $7M | Seed | Dec 08, 2022 |  |
| GigaMune | GigaMune was founded as a spin-out from GigaGen in 2017. They are combining unique insight into T cell responses to tumors with massively parallel T cell receptor (TCR) discovery to develop the next generation of T cell therapies. |  | Seed | Dec 01, 2022 |  |
| Notable Labs | Notable Labs is a personalized testing service for cancer patients that prioritizes combinations of FDA-approved treatments that can be immediately prescribed by a doctor without a clinical trial. | $189.2K | Series B | Jul 01, 2022 |  |

10 of 57 investments shown.

## Co-investors
- [Builders VC](https://shizune.co/investors/profile/builders) — VC Fund, 3 deals together
- [Harmonix Fund](https://shizune.co/investors/profile/harmonix-fund) — VC Fund, 3 deals together
- [CharmHealth](https://shizune.co/investors/profile/medicalmine-inc) — VC Fund, 3 deals together
- [Presight Capital](https://shizune.co/investors/profile/presight-capital) — VC Fund, 3 deals together
- [Sand Hill Angels](https://shizune.co/investors/profile/sand-hill-angels) — VC Fund, 3 deals together
- [Thiel Capital](https://shizune.co/investors/profile/thiel-capital) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund
- [NDRC](https://shizune.co/investors/profile/ndrc) — VC Fund
- [Act Venture Capital](https://shizune.co/investors/profile/act-venture-capital) — VC Fund

## Featured in investor lists
- [Consumer Investors in Ireland](https://shizune.co/investors/consumer-investors-ireland)
- [Health Care VC Funds in Ireland](https://shizune.co/investors/health-care-vc-funds-ireland)
- [Health Care Investors in Ireland](https://shizune.co/investors/health-care-investors-ireland)
- [Medical Device Investors in Ireland](https://shizune.co/investors/medical-device-investors-ireland)
- [Medical Device VC Funds in Ireland](https://shizune.co/investors/medical-device-vc-funds-ireland)
- [Hardware VC Funds in Ireland](https://shizune.co/investors/hardware-vc-funds-ireland)

## FAQ

### What does Bioverge invest in?

Bioverge invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 57 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Bioverge?

Public channels for Bioverge include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Bioverge?

The team at Bioverge includes Marianne Santaguida (Entrepreneur In Residence), Neil Littman (Founding Partner & CEO) and Rick Gibb (Founding Partner & COO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co